The European Commission approved the oral anticoagulant rivaroxaban for the prevention of atherothrombotic events after an acute coronary syndrome (ACS) in adult patients with elevated cardiac biomarkers.
Older patients treated with a high potency statin faced a 10 percent to 22 percent increased risk of new onset diabetes, according to results published online May 23 in BMJ. The authors of an accompanying editorial emphasized that the overall benefits outweigh the risks, “provided the treatment is targeted properly.”
ADVANCE, a study of 1,015 patients who underwent transcatheter aortic valve implantation (TAVI) using Medtronic’s CoreValve system, continued to show clinical benefits at one year. The results were presented May 21 at EuroPCR 2013 in Paris.
Patients with coronary heart disease (CHD) who received selective serotonin reuptake inhibitors (SSRIs) for six weeks had a lower rate of mental stress-induced myocardial ischemia compared with those who took placebos, according to results of the REMIT trial published May 22 in the Journal of the American Medical Association.
